In vivo performance testing of the novel Medspray wet aerosol inhaler
| Autor: | Jeroen Mathijn Wissink, Anne H. de Boer, Iwan Rutger Heskamp, Pieter Zanen, Wilbur de Kruijf, Paul Hagedoorn, Cees J.M. van Rijn, Henderik W. Frijlink, Paul Munnik |
|---|---|
| Přispěvatelé: | Pharmaceutical Technology and Biopharmacy, Biopharmaceuticals, Discovery, Design and Delivery (BDDD) |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.drug_class efficacy mild asthmatics Pharmaceutical Science Placebo deposition Double-Blind Method Bronchodilator Forced Expiratory Volume Administration Inhalation medicine Humans Pharmacology (medical) Albuterol Metered Dose Inhalers Particle Size VLAG Asthma Aerosols Cross-Over Studies Inhalation business.industry Inhaler optimal particle-size Nebulizers and Vaporizers Organic Chemistry respiratory system Middle Aged medicine.disease Organische Chemie Crossover study Aerosol respiratory tract diseases Bronchodilator Agents Anesthesia salbutamol Administration Salbutamol Female delivery business medicine.drug |
| Zdroj: | Journal of aerosol medicine and pulmonary drug delivery, 22(4), 317-321. MARY ANN LIEBERT, INC Journal of Aerosol Medicine and Pulmonary Drug Delivery 22 (2009) 4 Journal of Aerosol Medicine and Pulmonary Drug Delivery, 22(4), 317-321 |
| ISSN: | 1941-2711 |
| Popis: | Background: Monodisperse salbutamol inhalers were compared to select the optimal mass median aerodynamic diameter: 4.0, 5.0 or 6.0 mu m.Methods: Fifteen mild asthmatic patients participated. In all a FEV(1)-response of >12% (vs. baseline) or >200 mL after inhalation of 200 mu g salbutamol was measured. Each patient was studied four times with intervals of 1 week (three active and one placebo inhaler). First, 10 mu g salbutamol was administered, followed by 10, 20, and 40 mu g, resulting in cumulative doses of 10, 20, 40, and 80 mu g salbutamol. The FEV(1) and other lung function parameters were assessed at baseline and 30 min after inhalation of each consecutive dose. Five minutes later a next inhalation was given.Results: The 4.0- and 5.0-mu m droplets did not differ from placebo (p = 0.502, p = 0.127), but the 6.0-mu m droplets differed significantly (p = 0.003). The difference between 6.0-4.0 mu m droplets was significant (p = 0.020), but not between the 6.0-5.0 mu m droplets (p = 0.129). The FEV(1) increase after 80-mu g salbutamol for the 6.0-mu m droplets was 243 +/- 144 mL.Conclusions: The study showed that the 6.0-mu m droplets differed from the others in terms of FEV(1)-improvement, and hence, are the most efficacious of the three evaluated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|